Intellia Therapeutics Inc. Common Stock (NTLA)
Stock · NASDAQ · Health Care
$11.42as of 10/16/2026
Price chart
Active signals
NTLA Signal Track Record
How signals performed across all stocks →What NTLA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 31 | -7.6% | 32% | October 8, 2026 |
| Bollinger Band Breakout | 21 | -6.6% | 29% | October 9, 2026 |
| Bollinger Band Breakdown | 19 | -4.0% | 26% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 12 | -3.1% | 33% | September 22, 2026 |
| Any 20-session window (baseline) | -2.8% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NTLA
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. T…
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Employees
- 377
- Website
- www.intelliatx.com/
Fundamentals
- 1-day range
- $11.1$11.83
- Market cap
- $1.57B
- P/E (trailing)
- —
- P/E (forward)
- -4.42
- EPS (trailing)
- $-3.36
- Dividend yield
- —
- Beta
- 1.83
- Avg. volume
- 4.28M
How Intellia Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
18 analyst ratings
Intellia Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NTLAIntellia Therapeutics Inc. Common Stock$11.42▲ 0.71%Market cap $1.57BP/E —$7.95$28.25
- NNNNAnbio Biotechnology Class A Ordinary Shares$3.13▼ 5.15%Market cap $1.40BP/E 46.55$3.52$44.73
- QDELQuidelOrtho Corporation Common Stock$12.91▼ 7.19%Market cap $1.11BP/E —$9.92$35.58
- NEOGNeogen Corporation Common Stock$11.81▼ 3.75%Market cap $2.46BP/E —$5.37$14.26
- ACHVAchieve Life Sciences Inc. Common Shares$6.38▼ 8.46%Market cap $672.42MP/E —$2.62$8.64
- TKNOAlpha Teknova Inc. Common Stock$7.08▼ 6.84%Market cap $350.10MP/E —$1.91$9.48
- MYGNMyriad Genetics Inc. Common Stock$3.98▼ 8.51%Market cap $304.17MP/E —$2.74$8.59
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NTLA Intellia Therapeutics Inc. Common Stock | $1.57B | — | $11.42 | ▲ 0.71% | $7.95$28.25 |
| NNNN Anbio Biotechnology Class A Ordinary Shares | $1.40B | 46.55 | $3.13 | ▼ 5.15% | $3.52$44.73 |
| QDEL QuidelOrtho Corporation Common Stock | $1.11B | — | $12.91 | ▼ 7.19% | $9.92$35.58 |
| NEOG Neogen Corporation Common Stock | $2.46B | — | $11.81 | ▼ 3.75% | $5.37$14.26 |
| ACHV Achieve Life Sciences Inc. Common Shares | $672.42M | — | $6.38 | ▼ 8.46% | $2.62$8.64 |
| TKNO Alpha Teknova Inc. Common Stock | $350.10M | — | $7.08 | ▼ 6.84% | $1.91$9.48 |
| MYGN Myriad Genetics Inc. Common Stock | $304.17M | — | $3.98 | ▼ 8.51% | $2.74$8.59 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?Yahoo · 10/9/2026
- Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On ThursdayBenzinga · 10/8/2026
- Why Cathie Wood Is Taking Profits on AMD StockYahoo · 10/7/2026
- Nike downgraded, Home Depot initiated: Wall Street's top analyst callsYahoo · 10/6/2026
- Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST SharesYahoo · 10/6/2026
- Barclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8benzinga · 10/6/2026
- Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile UpBenzinga · 10/6/2026
- Barclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8Benzinga · 10/6/2026
- Intellia Therapeutics Q2 2026 Earnings Call TranscriptBenzinga · 10/5/2026
Insider Activity
Insider Actions →- Michael P. Dube · October 2, 2026 · Sale1.9K @ $12.43
- John M. Leonard · August 21, 2026 · Sale2.8K @ $13
- John M. Leonard · August 20, 2026 · Sale19.9K @ $12.6
- Edward J. Dulac III · July 22, 2026 · Sale8.1K @ $11.25
- Edward J. Dulac III · July 2, 2026 · Sale4.7K @ $18
- Michael P. Dube · July 1, 2026 · Sale2.6K @ $16.78
- Frank Verwiel · June 9, 2026 · Grant13.3K
- Frank Verwiel · June 9, 2026 · Grant9.2K
- Jesse Goodman · June 9, 2026 · Grant13.3K
- Jesse Goodman · June 9, 2026 · Grant9.2K
- Georgia Keresty · June 9, 2026 · Grant13.3K
- Georgia Keresty · June 9, 2026 · Grant9.2K
- Muna Bhanji · June 9, 2026 · Grant13.3K
- Muna Bhanji · June 9, 2026 · Grant9.2K
- William J. Chase · June 9, 2026 · Grant13.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 108.13M
- Total value held
- $1.37B
- Institutional holders
- 300
- Unknown14.51M
- Unknown12.16M
- Unknown6.92M
- Unknown5.73M
- Unknown5.08M
- Unknown4.71M
- Unknown3.70M
- Unknown3.26M
- Unknown2.85M
- Unknown2.70M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Intellia Therapeutics Appoints New Chief Medical Officer
Intellia Therapeutics announced the appointment of Jing L. Marantz as its new Chief Medical Officer. This leadership change occurred as the stock recently rose 7.6%, moving away from recent support levels. The news highlights a strategic shift in the company's medical leadership during a period of increased market activity.
Intellia Therapeutics Appoints New Chief Medical Officer. Intellia Therapeutics announced the appointment of Jing L. Marantz as its new Chief Medical Officer. This leadership change occurred as the stock recently rose 7.6%, moving away from recent support levels. The news highlights a strategic shift in the company's medical leadership during a period of increased market activity.